metastatic Cholangiocarcinoma (CCA) and Acute myeloid leukaemia (AML)

Roedd y cais yn rhannol lwyddiannus.

Dear Surrey and Sussex Healthcare NHS Trust,

Please can I request answers relating to the below questions. A national collation of this information will be made available to any trust requesting it in reply.

1. How many patients in the last 12 months has the trust treated for metastatic Cholangiocarcinoma (CCA) or Acute myeloid leukaemia (AML)?
a. For each of AML and CCA, how many have IDH-1 mutation?
b. How many CCA are intrahepatic vs extrahepatic?
i. How many of each of these present at 2nd line? How many of these at 2nd line have IDH-1 mutation?
c. For AML, how many patients were not fit for intensive chemotherapy? How many of these AML patients have IDH-1 mutation?

2. How many patients have been treated with pemigatinib (CCA), venetoclax plus azacitadine dual therapy or azacitadine monotherapy (AML )?
a. What is the average treatment duration for CCA patients treated with pemigatinib and AML patients treated with azacitadine dual therapy and azacitadine monotherapy? What is the preferred azacitadine product?

3. What is the real-world dosing for venetoclax (in combination with a CYP3A4)?
a. What is the antifungal of choice for patients treated with venetoclax?
b. What is the antifungal average treatment duration when used in combination with venetoclax ?
c) what proportion of patients are treated with an antifungal in combination with venetoclax? In what proportion of patients is the antifungal treatment stopped? In what proportion of these pts is the venetoclax dosage altered following cessation of the antifungal?

4. Do you routinely test CCA and AML patients for IDH-1 mutation?
a. If so when does the testing take place. E.g. at diagnosis or following 1st line progression? Is this done using NGS panel? Is this done using PCR testing?
B. What is the average turnaround time for these tests?

5. Who is responsible for the routine management of patients with CCA and AML?
a. Clinical oncologist / medical oncologist / specialist nurse etc?

6. How many admissions have occurred in the last 12 months for patients with CCA and AML?
a. What is their average length of stay?
b. How many of these patients were readmissions or readmitted during this time? If readmitted, can you state the main reason?

Thank you for taking the time to supply this information.

Yours faithfully,

Oliver Caswell

FOI (SURREY AND SUSSEX HEALTHCARE NHS TRUST), Surrey and Sussex Healthcare NHS Trust

1 Atodiad

Dear Oliver,

 

Thank you for your request for information which is now being handled
under the terms of the Freedom of Information Act 2000.

Your request is receiving attention and we will provide a response within
20 working days, that is, by 4 October 2022.

Please contact me if you have any queries in the interim, quoting our
reference (FOI 7162)  and I will be happy to help.

 

Kind regards,

Jeanette

 

Jeanette Randall
Freedom of information officer and communications support
Communications and marketing
Surrey and Sussex Healthcare NHS Trust
East Surrey Hospital, Redhill, RH1 5RH​

[1][Surrey and Sussex Healthcare NHS Trust request email]
[2]www.surreyandsussex.nhs.uk

 

Please note: I work remotely on Mondays and Fridays and Wednesday is my
non-working day

 

One Team l Compassion l Dignity and Respect l Safety and Quality

[3]cid:image004.png@01D71C18.3931D940

Follow us on social media: [4]Twitter ¦ [5]Facebook ¦ [6]LinkedIn ¦
[7]YouTube

 

 

 

 

 

dangos adrannau a ddyfynnir

FOI (SURREY AND SUSSEX HEALTHCARE NHS TRUST), Surrey and Sussex Healthcare NHS Trust

2 Atodiad

Dear Oliver,

Please see attached our response to your Freedom of Information request.

 

Kind regards,

Jeanette

 

 

Jeanette Randall
Freedom of information officer and communications support
Communications and marketing
Surrey and Sussex Healthcare NHS Trust
East Surrey Hospital, Redhill, RH1 5RH​

[1][Surrey and Sussex Healthcare NHS Trust request email]
[2]www.surreyandsussex.nhs.uk

 

Please note: I work remotely on Mondays and Fridays and Wednesday is my
non-working day

 

One Team l Compassion l Dignity and Respect l Safety and Quality

[3]cid:image004.png@01D71C18.3931D940

Follow us on social media: [4]Twitter ¦ [5]Facebook ¦ [6]LinkedIn ¦
[7]YouTube

 

 

 

 

 

dangos adrannau a ddyfynnir